Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

Business Wire March 3, 2021

Antibe Therapeutics Announces Closing of Bought Deal Public Offering

Business Wire February 24, 2021

IIROC Trade Resumption - ATE

Canada NewsWire February 18, 2021

IIROC Trading Halt - ATE

Canada NewsWire February 17, 2021

Antibe Therapeutics Announces C$35 Million Bought Deal Public Offering

Canada NewsWire February 17, 2021

OTC Markets Group Welcomes Antibe Therapeutics Inc. to OTCQX

PR Newswire February 16, 2021

Antibe Therapeutics Reports Q3 2021 Interim Financial and Operating Results

Business Wire February 12, 2021

Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance Pharma

Business Wire February 9, 2021

Antibe Therapeutics Virtually Opens The Market

Canada NewsWire February 8, 2021

Antibe Therapeutics Provides 2021 Corporate Update

Business Wire January 11, 2021

Antibe Therapeutics Strengthens Partnering Advisory Team With Appointment of Don Haut

Business Wire January 7, 2021

Antibe Therapeutics Announces Intent to Unify Intellectual Property Ownership

Business Wire December 18, 2020

Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation

Business Wire November 30, 2020

TMX Group, Antibe Therapeutics, C-Suite at The Open

Canada NewsWire November 26, 2020

Unmet Medical Need: Millions of Americans Could Benefit from Next-Generation NSAIDs

Livemoney November 24, 2020

Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors

Business Wire November 24, 2020

Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing

Business Wire November 17, 2020

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

Business Wire November 13, 2020

Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange

Business Wire November 10, 2020

Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Business Wire October 30, 2020